<h1>UK-US deal sets three-year zero tariffs on UK medicines, boosts pharma investment, jobs, and health treatment spending</h1> The UK and US concluded a trade arrangement establishing a zero-tariff regime on UK-origin pharmaceuticals, ingredients, and medical technology exported to the US for at least three years. In exchange, UK pharmaceutical companies will increase investment and job creation in the US, while the UK government will raise spending on new and effective treatments by about 25 percent. The agreement forms part of a broader bilateral trade framework under which the US plans to cut import duties on certain UK goods in return for expanded access for US products in the UK market, deepening regulatory and trade cooperation in the life sciences sector.